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Abstract
Background Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for relapsing-remitting
multiple sclerosis (RRMS).
Objectives To assess the effectiveness and safety of fingolimod in patients with RRMS in real-world clinical practice in Portugal.
Methods Retrospective, multicentre, non-interventional study, reporting 3 years follow-up of data collected from October 2015
to July 2016. Sociodemographic data and previous treatments at baseline and data regarding disease evolution, including number
of relapses, annualised relapse rates (ARR) and Expanded Disability Status Scale (EDSS), were collected.
Results Two-hundred and seventy-five participants were enrolled in the REALMS study. Results showed that the main reason to
switch to fingolimod was failure of previous treatment (56.7%) and only 3.6% were naïve patients. In the total population, there
was a significant decrease in ARR of 64.6% in the first year of treatment, 79.7% in the second year and 82.3% in the third year,
compared with baseline. More than 67.0% of patients had no relapses during the 3 years after switching to fingolimod. EDSS
remained stable throughout the study.
Conclusions Therapy with fingolimod showed a sustained effectiveness and safety over the 3 years, particularly on patients
switched from first-line drugs (BRACE). No new safety issues were reported.
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Introduction
Fingolimod belongs to a class of drugs that targets the
sphingolipid-regulated signaling system, acting as a function-
al antagonist of the sphingosine-1-phosphate type 1 (S1P1)
receptor immunomodulatory [1], although some authors
consider it to be an immunosuppressant [2]. It is a prodrug
that is phosphorylated by sphingosine kinases to its active
form, phosphofingolimod [1]. S1P1 is expressed abundantly
on T and B lymphocytes, and fingolimod induces its down-
regulation by sequestering T cells in lymph nodes. This action
prevents these cells from infiltrating inflammatory lesions in
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the central nervous system (CNS) [3], and fingolimod has
been shown to decrease the pro-inflammatorymarker IL-6 [4].
Fingolimod has shown to be effective in all four key mea-
sures of disease activity (relapse rate, disability progression,
magnetic resonance imaging activity, and brain volume loss)
compared with placebo or intramuscular interferon beta-1a in
three pivotal clinical trials [5–7], although no differences were
detected in the time to the confirmed progression of disability
in the TRANSFORMS study, given its short duration (12
months) [6].
Fingolimod (Gilenya®) is the first approved oral disease-
modifying therapy (DMT) worldwide. In the European Union
[8], as well as in Portugal [9], fingolimod was approved as a
single DMT in adult and paediatric patients aged 10 years and
older [10] with highly active relapsing-remitting multiple scle-
rosis (RRMS) despite a full and adequate course of treatment
with at least one DMT or patients with rapidly evolving severe
RRMS defined by two or more disabling relapses in one year,
and with one or more gadolinium-enhancing lesions on brain
magnetic resonance imaging (MRI) or a significant increase in
T2 lesion load as compared with a previous recent MRI.
Several studies of fingolimod in real-world populations
have been published [11–15] confirming its effectiveness
and safety shown in clinical trials in a more heterogeneous
population.
The aim of the present study was to provide further data on
the effectiveness and safety of fingolimod in a real-world clin-




REALMS was a retrospective, multicentre, national non-
interventional study. Medical records were used to collect
real-world evidence for the effectiveness and safety of
fingolimod, as well as demographic and clinical characteris-
tics of these patients. The study was conducted according to
the tenets of the Declaration of Helsinki in its latest amend-
ment (Brazil, 2013) and was approved by the Ethics
Committee of each participating centre.
Setting and participants
REALMS was a Portuguese multicentre study that retrospec-
tively collected real-world evidence on the effectiveness, tol-
erability and safety from the clinical records of RRMS patients
under fingolimod treatment in the most representative
Portuguese MS centres. This paper reports 3-year follow-up
of data collected from the 9 participating centres throughout
Portugal from October 2015 to July 2016.
Inclusion criteria were as follows: age 18 years or more;
diagnosis of RRMS according to the McDonald Criteria from
2010 [16]; patients who had initiated treatment with
fingolimod at least 12 months before study enrolment, includ-
ing those previously treated with interferon-β and/or
glatiramer acetate, natalizumab or treatment naïve; at least
12 months of follow-up after initiating fingolimod treatment
and sufficient data available on the clinical files. Treatment
could have been discontinued, either temporarily or perma-
nently, during these 12 months of follow-up (in case of tem-
porary discontinuation, date of treatment initiation has been
considered the date of the first administration of fingolimod);
and patients that accepted to participate in the study and pro-
vided written informed consent to collect and analyse their
data.
Exclusion criteria were patients who had previously been
treated with fingolimod in a clinical trial before the inclusion
in this study and had progressive course ofMS (either second-
ary or primary progression) at the date of fingolimod treatment
initiation.
Collected variables and definitions
All variables were collected on an eCRF specifically designed
for the study. The following data were obtained for all patients
at baseline (12 months after initiation of fingolimod): age, sex,
disease duration, date of first relapse, prevalence of other
symptoms of MS, previous DMTs, duration of previous treat-
ment with interferon-β or glatiramer acetate or natalizumab,
reasons to switch to fingolimod, annualised relapse rates
(ARR) and Expanded Disability Status Scale (EDSS) before
switching to fingolimod, relevant comorbidities, and concom-
itant treatments. At follow-up, the following variables were
collected: number of relapses, days to first relapse, ARR,
EDSS, relevant comorbidities, treatment with costicosteroids,
adverse events (AEs), fingolimod discontinuation, when ap-
plicable, and reason for discontinuation. A relapse was de-
fined as patient-reported symptoms or objectively observed
signs typical of an acute inflammatory demyelinating event
in the CNS, current or historical, with duration of at least 24
hours, in the absence of fever or infection [16]. Progression of
disability was defined as a 1-point increase in the EDSS score
(or a half-point increase for patients with a baseline score
above 5.0) that was confirmed at 6 months for up to 24months
[17].
Quantitative variables and groups
In addition to descriptive statistics, inference statistics was
performed in the whole population and three subgroups de-
pending on treatment previous to fingolimod: naïve,
interferon-β/glatiramer acetate or natalizumab. ARR and
EDSS in the previous year and during the first 12, 24 and 36
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months of treatment with fingolimod were compared. The
proportion of relapse-free patients was also compared between
these time points. The difference between these variables over
time, within the same group, was also assessed.
Safety assessments
The safety assessments analysed were as follows: de-
scriptives of AEs during the first 24 h of the first
fingolimod administration; description of AEs occurring
after fingolimod treatment initiation; and maintenance of
treatment during the first year of treatment with
fingolimod. Disease activity, e.g. relapses or progres-
sion, were considered AEs.
Statistical methods
An intent-to-treat (ITT) statistical analysis was performed.
According to the original statistical analysis plan (SAP), sta-
tistical analysis was performed with available data, and no
method of imputation for missing data was used.
Quantitative variables were tested for normality using the
Shapiro-Wilk test. Since the majority of quantitative variables
were not normally distributed, baseline median, interquartile
range (IQR), minimum and maximum are presented. For cat-
egorical variables, number and percentage of total are present-
ed. Within-group analyses for quantitative variables were per-
formed using the Friedman test and adjusted for multiple com-
parisons using the Sidak correction. For categorical variables,
Cochran’s Q statistics or McNemar’s test were used as appro-
priate. The Kendall’s W test was used to analyse correlations.
Between-group analyses for quantitative variables were per-
formed using the Kruskal-Wallis test and adjusted for multiple
comparisons using the Sidak correction. For categorical vari-
ables, the χ2 test was used. The Spearman ρ or Kendall’s τ-b
were used to analyse correlations as appropriate. Predictors of
EDSS at 3 years and ARR at 1, 2 and 3 years after switching to
fingolimod were analysed using multivariate regressions
using the backward conditional method. The dependent vari-
able on the EDSS model was EDSS at 3 years, and the inde-
pendent variables were sex, age, ARR in the year before
switching to fingolimod, number of previous DMTs and years
until switch to fingolimod. On all ARR models, the indepen-
dent variables were the same as the ones included in the EDSS
model plus: (1) baseline EDSS for the dependent variable
ARR at 1 year; (2) baseline EDSS and ARR at 1 year for
the dependent variable ARR at 2 years; and (3) baseline
EDSS, ARR at 1 year and ARR at 2 years for the dependent
variable ARR at 3 years. EDSS at baseline was not included in
the predictor model of EDSS since these variables were sig-
nificantly correlated (n = 37, Spearman ρ = 0.754, p = 0.01). A
significance level of α = 0.05 was used (two sided). The soft-
ware used was the SPSSv20.0 statistical package.
Results
Patient population
The REALMS study included 275 participants. All tables and
figures state the number of patients with data available for
each analysed variable and each time point. Missing data were
considered to be missing completely at random (MCAR).
Forty-one (14.9%) patients discontinued treatment with
fingolimod during the study, twenty-seven (9.8%) of which
permanently and fourteen (5.1%) temporarily. Therefore, the
overall attrition rate of enrolled patients was 9.8%.
Demographics and clinical baseline characteristics
Demographic and clinical characteristics of the total popula-
tion and the three subgroups are described in Table 1. The 13
patients missing from Table 1 had previous treatments other
than BRACE or natalizumab (off-label azathioprine (n = 4),
mitoxantrone (n = 4), Ig IV (n = 4) and methotrexate (n = 1)).
The majority of patients were women (~ 65%). The median
age at diagnosis for the total cohort and subgroups was be-
tween 40.0 and 43.0 years old, with the exception of the naïve
subgroup who was younger (36.5 years). The median (IQR)
disease duration was 10.0 (9.0) years. As expected, the naïve
sub-group presented significant less years of disease duration
compared with the interferon-β/glatiramer acetate and
natalizumab sub-groups (4.5 vs. 10.0 and vs. 12.0 years, re-
spectively, p < 0.05).
Reasons to switch to fingolimod
The reasons to switch to fingolimod therapy were, in decreas-
ing order of frequency, failure of previous treatment (56.7%),
natalizumab withdrawal due to progressive multifocal
leukoencephalopathy risk (35.3%) or other, such as adverse
events from other treatments (6.2%). The remaining 3.6%
were naïve patients with rapid disease progression, who initi-
ated fingolimod as first-line therapy.
Annualised relapse rate
Considering the total population, there was a 64.6% decrease
in ARR (0.79 vs. 0.28, p < 0.001) in the first year of treatment
(Fig. 1). ARR further decreased by 79.7% in year 2 and 82.3%
in year 3 compared with baseline (0.79 vs. 0.16 and vs. 0.14,
respectively, p < 0.001). Patients previously treated with
interferon-β or glatiramer acetate therapies showed an ARR
reduction of 76.3% from baseline to year 1 post-fingolimod
treatment (0.93 vs. 0.22, p < 0.001). ThemeanARR decreased
by 87.1% in year 2 (0.12, p < 0.001) and 84.9% in year 3
(0.14, p < 0.001) compared with baseline. Patients previously
treated with natalizumab (n = 83) did not show a significant
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reduction of ARR in the first year of treatment. However, in
these patients, ARR decreased by 48.8% in year 2 (0.43 vs.
0.22, p < 0.002) and 62.7% in year 3 (0.43 vs. 0.16, p < 0.001)
compared with baseline.
Therapy with fingolimod showed a sustained effectiveness
over the 3 years.
Expanded Disability Status Scale
The median baseline EDSS in the whole REALMS popula-
tion was 3.00, changed to 2.50 after 1 year of fingolimod
treatment (p > 0.05) and remained stable up to the end of the
3-year follow-up (Fig. 2a). When analysing by previous
DMTs, both the previous interferon-β or glatiramer acetate
and previous natalizumab groups remained with a stable
EDSS over the 3 years of fingolimod therapy (Fig. 2b).
Between group analyses showed that the interferon-β or
glatiramer acetate group presented a significantly lower medi-
an EDSS compared with natalizumab 1 year after fingolimod
therapy (p < 0.05), with both sub-groups remaining stable
without differences between them after 2 and 3 years of
fingolimod therapy.
Relapse-free patients
Considering all patients of the REALMS study, 78.9 to 90.5%
were relapse free in each of the 3 years of this study. From













0.00 0.20 0.40 0.60 0.80 1.00
Natalizumab










































All REALMS patients previous year (n=275) 1st year (n=275) 2nd year (n=256) 3rd year (n=248)
I n t e r f e r o n β o r
g l a t i r a m e r a c e t a t e previous year (n=169) 1st year (n=169) 2nd year (n=169) 3rd year (n=162)
Natalizumab previous year (n=83) 1st year (n=83) 2nd year (n=83) 3rd year (n=81)
Fig. 1 ARR before and after
fingolimod therapy in the whole
REALMS population and
according to previous disease-
modifying therapies. Error bars
represent 95% CIs. See text for
p values of comparisons not
marked with ns
Table 1 Demographics and clinical characteristics at fingolimod treatment initiation
Characteristic Total cohort (n = 275) Prior interferon-β or glatiramer acetate (n = 169) Prior NTZ (n = 83) Naïve (n = 10)
Female (n (%)) 179 (65.1) 114 (67.5) 52 (62.7) 5 (50.0)
Disease duration (year; median (IQR)) 10.0 (9.0; n = 273) 10.0 (8.0; n = 167) 12.0 (7.0)* 4.5 (9.0)**
Age (year; median (IQR)) 41.0 (12.0) 43.0 (14.0) 40.0 (11.0) 36.5 (11.0)
EDSS score (median (IQR)) 3.0 (2.0; n = 150) 2.5 (2.0; n = 88) 3.5 (2.5; n = 48) 2.8 (2.5; n = 8)
Prior treatments (median (IQR)) 2.0 (2.0) 2.0 (2.0) 3.0 (1.0) N/A
Data regarding subgroups by prior therapy analysed the last therapy before switching to fingolimod. The 13 patients missing had previous treatments
other than BRACE or natalizumab (off-label azathioprine (n = 4), mitoxantrone (n = 4), Ig IV (n = 4) and methotrexate (n = 1))
NTZ, natalizumab; N/A, not applicable; IQR, interquartile range; n, number of patients
*p = 0.021 compared with interferon-β or glatiramer acetate; **p < 0.05 compared with interferon-β or glatiramer acetate and NTZ
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vs. 87.3%, p = 0.016) and from years 1 to 3, further increased
to 90.5% (p < 0.001). More than 67.0% of patients had no
relapses during the 3 years after switching to fingolimod.
Adverse events
There were a total of 61 (22.2%) AEs in 49 (17.8%) patients
(Table 2). AEs were mostly related to disease activity (5.5%),
followed by reductions in lymphocyte counts, opportunistic
infections, increased liver enzymes and hypertension. None of
these AEs were classified as serious AEs (SAEs).
Multivariate regression analyses
Predictors of EDSS at 3 years and ARR at 1, 2 and 3 years
after switching to fingolimod were analysed with multivariate
regressions using the backward conditional method (Table 3).
Age in years and years until switch to fingolimod were posi-
tive predictors of EDSS at 3 years. Prior number of DMTs was
a positive predictor of ARR at 1 year, and ARR at 1 year was a
positive predictor of ARR at 2 years. None of the variables
was a predictor of ARR at 3 years.
Discussion
This study aimed to characterise the patients’ profile treated
with fingolimod in the Portuguese real-word clinical practice,
as well as to assess its effectiveness and safety.
In Portugal, the effectiveness and safety of fingolimod in a
real-word population was previously studied in two single-
centre studies [11, 18]. A multicentric study was necessary to
contribute to the validation of the reported data. In these two
studies, the reported discontinuation rate was 10.6% [11] and
15.6% (at 12 months) [18]. These attrition rates are similar to
the ones found in the present study (9.8%), which are also
similar to the ones reported by the real-word study with
fingolimod from UK (approximately 8%) [13]. In other two
real-world studies, one conducted in the Czech Republic, the
GOLEMS study, 11.3% of patients discontinued fingolimod at
Table 2 Adverse events by year
after initiating fingolimod
treatment
Adverse event Year 1 Year 2 Year 3 Total by AE
N (%) N (%) N (%) N (%)
Opportunistic infections 2 (0.7) 3 (1.1) 1 (0.4) 9 (3.3)a
Grade 4 lymphopenia (< 200 cells/μl) 8 (2.9) 3 (1.1) 0 (0.0) 11 (4.0)
Hepatic enzymes > 3 × ULN 5 (1.8) 2 (0.7) 0 (0.0) 8 (2.9)a
Hepatic enzymes > 5 × ULN 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.4)
Hypertension 0 (0.0) 1 (0.4) 1 (0.4) 2 (0.7)
Elevation of blood pressure 0 (0.0) 2 (0.7) 0 (0.0) 2 (0.7)
Disease activity (relapses, progression) 9 (3.3) 2 (0.7) 3 (1.1) 15 (5.5)a
Headaches 3 (1.1) 0 (0.0) 0 (0.0) 3 (1.1)
Other 8 (2.9) 2 (0.7) 0 (0.0) 10 (3.6)
Total by year 36 (13.1) 15 (5.5) 5 (1.9)
N, number of patients; %, percentage of total; ULN, upper limit of normal
a Three opportunistic infections, one hepatic enzymes > 3 × ULN and one disease activity could not be assigned to
a specific year given the dates are lacking
Fig. 2 EDSS over time. Error bars represent 95% CIs. a Including all REALMS patients. p = ns for all comparisons. b According to previous disease-
modifying therapies (DMTs). p = ns for all comparisons
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or before 12 months [19] and another one conducted in Spain,
the MS NEXT, 3.9% of patients permanently discontinued
fingolimod during the first year of treatment [20].
Overall, the proportion of relapse-free patients significantly
increased from 78.9 to 90.5% from the first to the third year
after switching to fingolimod therapy. Moreover, 67% of the
patients had no relapses during the 3 years after switching to
fingolimod. These results are in accordance with the findings
by Mazibrada et al and the MS NEXT study that reported
83.7% relapse-free patients 12 months after fingolimod initi-
ation [13], and 67% relapse-free patients after two years of
fingolimod treatment [20], respectively. The GENIUS study
concluded that fingolimod appeared to be effective in naïve
patients and after first-line treatment failure in reducing risk of
relapse and disease activity throughout a 2-year follow-up
[21]. In the two Portuguese real-world studies, the percentage
of relapse-free patients at year 1 after switching to fingolimod
was 75% [11] and 80.4% [18]. However, in this last study, the
percentage of relapse-free patients decreased from years 1 to 3
of fingolimod treatment. Nevertheless, the percentage of pa-
tients with no relapses during the 3 years of fingolimod treat-
ment was 60.8% [18], similar to that observed in our study.
Considering the total population and the group switching
from interferon-β/glatiramer acetate, ARR significantly de-
creased in the first year of treatment with fingolimod and
remained lower than baseline over 3 years. These results are
in accordance with those reported by the PANGAEA study
after 5 years of fingolimod therapy [22], a study conducted
with similar methodological characteristics as the current
study [23]. These results are also consistent with previously
reported Portuguese studies whose results also showed a de-
crease in ARR in the first year of treatment with fingolimod
[11, 18] and with the MS NEXT study that reported a 76%
decrease in ARR after 2 years of fingolimod [20].
Mazibrada et al. reported that ARR in patients switching
from natalizumab to fingolimod significantly decreased after
the first year of fingolimod treatment [13], and the
PANGAEA study at 4 years showed a decrease in ARR after
the first year of fingolimod treatment that was maintained
through 4 years, compared with baseline [24]. Our results
showed that in the group of patients switching from
natalizumab, there was no reduction of ARR in the first year
of fingolimod treatment, although ARR decreased in years 2
and 3 compared with baseline. These results are in line with
the ones reported by the two Portuguese real-world studies
[11, 18].
Regarding disability, and as observed in the majority of stud-
ies [22, 25–27], the median value of EDSS at baseline was 3.0.
Within-group analyses over time showed that EDSS remained
stable over the 3 years after switching to fingolimod regardless of
previous interferon-β/glatiramer acetate therapies. These results
are in line with the FREEDOMS II and TRANSFORMS trials
[6, 28]. Recently published results of real-world studies also
showed a stable EDSS after switching to fingolimod, regardless
of previous therapy [11, 13, 18, 22, 24].
Disability progression independent of relapse activity
(PIRA) has been described as a frequent phenomenon in pa-
tients classified as RRMS. As a matter of fact, the term silent
progression was recently proposed to describe the insidious
disability that accrues in many patients who satisfy traditional
criteria for RRMS. Therefore, we think that these results reflect
precisely this phenomenon, since not all patients included in
this cohort fulfil the criteria for secondary progressive MS.
This suggests that the same process that underlies SPMS likely
begins far earlier than it is generally recognised and supports a
unitary view of MS biology, with both focal and diffuse tissue
destructive components, and with inflammation and neurode-
generation occurring throughout the disease spectrum [29].
Interestingly, between-group analysis showed that the
interferon-β/glatiramer acetate group presented a significantly
lower median EDSS compared with natalizumab 1 year after
fingolimod therapy and remained stable over the ensuing 2 years.
These results have not been shown in the FREEDOMS,
FREEDOMS II and TRANSFORMS trials [5, 6, 28], and are
most probably a consequence from the fact that most patients
switched to fingolimod based on clinical activity (relapses) in
close temporal association with the time of switch. In line with
this hypothesis, EDSS decreases were mostly due to switches
from interferon-β/glatiramer acetate and not observed in the
group that switched from natalizumab, in which the primary
reason for the switch was not lack of efficacy, but being seropos-
itive for the John Cunningham virus.
Table 3 Predictors of EDSS at 3 years and ARR at 1, 2, and 3 years after switching to fingolimod
Predictors EDSS 3 years ARR 1 year ARR 2 years ARR 3 years
Exp(B) 95% CI p value Exp(B) 95% CI p value Exp(B) 95% CI p vale Exp(B) 95% CI p value




ARR 1 year 1.077 1.014–1.143 0.017 – – –
Prior DMTs (n) 1.028 1.008–1.050 0.007
Statistically non-significant variables are not reported in the final model
95% CI, 95% confidence interval for Exp(B); DMT, disease modifying therapies
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On multivariate regression analysis, the higher the age and
the years until switch to fingolimod the higher the EDSS after
3 years. Also, the higher the number of previous DMTs the
higher the ARR at year 1 after fingolimod initiation, and the
higher the ARR at 1 year the higher the ARR at 2 years after
fingolimod initiation. Taken together, and from a clinical
standpoint, the faster the switch to fingolimod the better the
results for the patient.
A sensitivity analysis for EDSS predictors at 3 years con-
sidering only patients that completed the 3-year follow-up (n =
52) has been performed. Age remained a positive predictor,
although with slightly different values (Exp(B), 1.111; 95%
CI, 1.043–1.183; p = 0.002), years until switch to fingolimod
was no longer a predictor of EDSS at 3 years but prior DMTs
were (Exp(B), 1.528; 95% CI, 1.021–2.289; p = 0.040). In
fact, these two variables have the same interpretation and the
conclusion to be drawn is the same: the early treatment with
fingolimod is the real predictor of EDSS at 3 years, regardless
if it is measured by proxy in years until switch to fingolimod
or in prior DMTs. Therefore, this sensitivity analysis
strengthens our results and conclusions.
In line with trials and real-world data, we observed no
significant differences in ARR 1 year after switching from
natalizumab to fingolimod whereas when changing from pre-
vious interferon-β/glatiramer acetate, the improvement of
ARR at 1 year was evident.
In our population, and similar to other studies [11, 15, 18,
19, 30], fingolimod has shown to have a good safety profile.
The proportion of patients discontinuing treatment was mostly
related to disease activity (5.5%).
In RRMS, inflammation and the consequent presence of
lymphocytes in the CNS is a hallmark of the disease, occur-
ring in all its stages and courses. Therefore, new therapies that
could act as promoters of the redistribution of lymphocytes
back into circulation may reduce the immunomodulated axo-
nal attack [31]. Thereby, previous treatment could hinder
baseline parameters of inflammatory activity and future re-
lapses induced by specific treatment. Perhaps this explains
our results that showed that the time until switch to fingolimod
was a predictor of higher EDSS at 3 years and a higher number
of previous DMTs was a predictor of higher ARR at year 1
after fingolimod initiation.
Limitations and strengths
REALMS had the inherent limitations of secondary data col-
lection. There were too many missing MRI data to allow for
an analysis of these parameters. Also, and although all inves-
tigators have been asked to record all adverse events, this is
impossible to guarantee. One of the biggest strengths of this
study was the large sample size. This was the largest
observational study done up to date, involving 9 of the most
important MS centres in Portugal.
Conclusions
The REALMS study provides real-world data confirming the
effectiveness and safety of fingolimod under real-world con-
ditions, in the Portuguese population, consistent with phase 3
trials. Fingolimod is an effective treatment in real-world pop-
ulations with RRMS regardless of previous DMTs. Moreover,
significant reductions in relapses were seen after switching
from interferon-β or glatiramer acetate to fingolimod, sug-
gesting that these patients benefit from switching to
fingolimod. Fingolimod revealed to be a good option treat-
ment for the majority of patients after switch from
natalizumab, since most of these patients were relapse free
(88.9%) and free from progression of disability (66.7%) after
3 years of treatment with fingolimod. Furthermore, these data
suggest that the earlier the treatment with fingolimod, the bet-
ter the outcomes for patients with RRMS.
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